Results 221 to 230 of about 30,028 (235)

Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia

Journal of Pediatrics, 2015
D Meeike Kusters, Claude Gagné, Marc S Jacobson   +2 more
exaly  

Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects with Heterozygous Familial Hypercholesterolemia

Journal of Pediatrics, 2010
Frederick J Raäl, Daniel Schurr, Soamnauth Misir   +2 more
exaly  

Prevalence Of Heterozygous Familial Hypercholesterolemia In Kuwait

Atherosclerosis, 2019
R. Al-Laho, Z. Al-Muhanna, J. Hussain, A. Alsarraf   +3 more
openaire   +1 more source

Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up

Angiology, 2018
Ioannis Skoumas, Nikolaos Ioakeimidis, Christina Chrysohoou   +2 more
exaly  

Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy

Journal of Pediatrics, 2006
Helena Gylling
exaly  

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Circulation, 2012
Frederick J Raäl, Ransi Somaratne, Scott M Wasserman   +2 more
exaly  

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.

Journal of Clinical Lipidology, 2017
J. Kastelein, G. Hovingh, G. Langslet, M. Baccara-Dinet, D. Gipe, U. Chaudhari, Jian Zhao, P. Minini, M. Farnier   +8 more
semanticscholar   +1 more source

The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients

Journal of Clinical Lipidology, 2016
Sophie Beliard, Aurélie Millier, Valerie Carreau   +2 more
exaly  

Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review

American Journal of Epidemiology, 2004
Steve E Humphries, Humphries Steve E
exaly  

Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.

American Journal of Cardiology, 2018
D. Karalis, U. Mallya, A. Ghannam, J. Elassal, Rishab A Gupta, S. Boklage   +5 more
semanticscholar   +1 more source